September 2025
1. PENG D, Hu X, Huang J, Li Q, et al
   Coordinated role of RIG-I, MDA5, and TLR7 in the innate immune response to duck hepatitis A virus 3.
   Arch Virol. 2025;170:211.
   

   >> Share

   
   August 2025
2. ZADEH MEHRIZI T, Eshrati B, Ebrahimi Shahmabadi H
   Evaluation of recent pre-booster studies on hepatitis B vaccine effectiveness across WHO regions with HBV prevalence above 1% in the general population up to 60 years of age: a systematic review.
   Arch Virol. 2025;170:193.
   

   >> Share

   
   May 2025
3. SLEEM R, Salah A, Alziz AA, Daif AA, et al
   Inhibition of hepatitis C virus replication in HepG2 cells via modulation of the Raf-1 and interferon-alpha signaling pathways by thymoquinone.
   Arch Virol. 2025;170:120.
   

   >> Share

   
   
4. DA SILVA H, Juniastuti, Amin M, Soares J, et al
   Genotypes, subtypes, and genetic variability of hepatitis B virus from blood donors in Timor-Leste.
   Arch Virol. 2025;170:119.
   

   >> Share

   
   March 2025
5. SUPEKAR R, Sarkar J, Chakrabarti P, Biswas S, et al
   Diagnostic challenges due to hepatitis B virus surface antigen mutations outside the major hydrophilic region.
   Arch Virol. 2025;170:71.
   

   >> Share

   
   December 2024
6. BIRLEM GE, Sita A, Gularte JS, de Souza da Silva D, et al
   Detection of a novel hepacivirus in wild cavies (Cavia aperea aperea).
   Arch Virol. 2024;170:19.
   

   >> Share

   
   November 2024
7. TRIPATHY AS, Wagh P, Shahapure G, Walimbe AM, et al
   Association of IL1RN VNTR and NKG2A polymorphisms with hepatitis E infection, a case study from western India.
   Arch Virol. 2024;169:250.
   

   >> Share

   
   
8. JIAO Q, Zhu S, Liao B, Liu H, et al
   An NLR family member X1 mutation (p.Arg707Cys) suppresses hepatitis B virus infection in hepatocytes and favors the interaction of retinoic acid-inducible gene 1 with mitochondrial antiviral signaling protein.
   Arch Virol. 2024;169:238.
   

   >> Share

   
   
9. ALMAS I, Tariq S, Amin I, Shahid M, et al
   Molecular epidemiology and genetic characterization of hepatitis B virus in two major provinces of Pakistan.
   Arch Virol. 2024;169:239.
   

   >> Share

   
   October 2024
10. KHAN S, Aggarwal S, Bhatia P, Yadav AK, et al
    Glucose and glutamine drive hepatitis E virus replication.
    Arch Virol. 2024;169:233.
    

    >> Share

    
    September 2024
11. NJIFON AM, Modiyinji AF, Monamele CG, Mbouyap PR, et al
    A decade-long retrospective study of hepatitis C virus genetic diversity in Cameroon, 2013-2023: presence of a high proportion of unsubtypable and putative recombinant HCV strains.
    Arch Virol. 2024;169:197.
    

    >> Share

    
    June 2024
12. SHALABY S, Awadin W, Karam R, Salem S, et al
    Pathological and phylogenetic characterization of a rare fowl adenovirus (FAdV-8b) associated with inclusion body hepatitis in naturally infected Meleagris gallopavo.
    Arch Virol. 2024;169:146.
    

    >> Share

    
    April 2024
13. DAS S, Behera P, Shewale DJ, Bodele J, et al
    Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
    Arch Virol. 2024;169:112.
    

    >> Share

    
    
14. SEDOHARA A, Takahashi K, Arai K, Arizono K, et al
    Characterization of mutations in hepatitis B virus DNA isolated from Japanese HBsAg-positive blood donors in 2021 and 2022.
    Arch Virol. 2024;169:103.
    

    >> Share

    
    
15. WANG S, Xie Y, Liu F, Wang J, et al
    miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2.
    Arch Virol. 2024;169:88.
    

    >> Share

    
    February 2024
16. SAID EM, Abdulaziz BA, Kassas ME, El Attar IH, et al
    Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir the
    Arch Virol. 2024;169:45.
    

    >> Share

    
    January 2024
17. MA X, Li Y, Zhu H, Lu K, et al
    ENPP1 inhibits the transcription activity of the hepatitis B virus pregenomic promoter by upregulating the acetylation of LMNB1.
    Arch Virol. 2024;169:36.
    

    >> Share

    
    
18. GUPTA S, Parveen S
    Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approach.
    Arch Virol. 2024;169:33.
    

    >> Share

    
    October 2023
19. GAO H, Fan H, Xie H
    miR-HCC2 suppresses hepatitis B virus replication by inhibiting the activity of the enhancer I/X promoter.
    Arch Virol. 2023;168:282.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share